Form 4: ZimVie Inc. Director Sally Crawford Reports Acquisition of Deferred Share Units and Restricted Stock Units

Director Sally Crawford reports acquisition of deferred share units and restricted stock units in ZimVie Inc.

Summary

• On May 15, 2024, Sally Crawford, a director of ZimVie Inc., acquired 500 deferred share units and 11,012 restricted stock units.
• The deferred share units were accrued under the company's Deferred Compensation Plan for Non-Employee Directors.
• These units will be settled in shares of ZimVie Inc. common stock within 60 days after Crawford's service as a director ends.
• The restricted stock units are immediately 100% vested but subject to mandatory deferral until the later of Crawford's termination of service as a director or three years after the grant date.
• Following these transactions, Crawford directly owns 6,255.864 shares of common stock and 36,609 restricted stock units.
• A Power of Attorney was executed on May 1, 2024, granting Heather J. Kidwell, Kristi Lehman, and Christine G. Long the authority to act on Crawford's behalf for SEC filings.

Sentiment

Score: 7

Explanation: The document is a routine SEC filing indicating standard compensation practices. It doesn't contain overtly positive or negative information, but the equity grants suggest confidence in the company's future.

Positives

• The acquisition of deferred share units and restricted stock units indicates continued alignment of the director's interests with the company's long-term performance.
• The immediate vesting of restricted stock units, although subject to deferral, suggests confidence in the company's future prospects.

Future Outlook

The deferred share units will be settled in shares of common stock within sixty days after cessation of the reporting person's service as a Director. The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date.

Industry Context

This filing is a routine disclosure related to director compensation and equity ownership, common in publicly traded companies. It reflects standard practices for aligning director interests with shareholder value through equity-based compensation.

Comparison to Industry Standards

• Equity compensation for board members is a common practice across the medical device industry, with companies like Medtronic, Stryker, and Johnson & Johnson using similar instruments such as restricted stock units and deferred compensation plans.
• The vesting and deferral terms are also typical, designed to incentivize long-term commitment and alignment with shareholder interests.
• The specific amounts of equity granted would be benchmarked against peer companies based on market capitalization, board compensation policies, and individual director roles and responsibilities.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning director interests with long-term company performance.
• Employees may see this as a reflection of the company's commitment to its leadership.

Key Dates